Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Annexon Biosciences ( (ANNX) ) just unveiled an update.
Annexon Biosciences has appointed William Jones to its Board of Directors, bringing his extensive 30-year experience in the biotechnology industry to the company. This strategic move comes as Annexon prepares for the commercialization of key treatments for Guillain-Barré Syndrome and geographic atrophy, with Jones’ commercial expertise expected to enhance the company’s market positioning and execution of its commercialization strategies.
More about Annexon Biosciences
Annexon Biosciences is a biopharmaceutical company focused on developing novel therapies for neuroinflammatory diseases affecting the body, brain, and eye. They leverage a unique approach targeting the C1q molecule in the classical complement pathway, aiming to prevent neuroinflammation and tissue damage. Their pipeline includes investigational drugs for autoimmune, neurodegenerative, and ophthalmic diseases, addressing the needs of over 8 million people globally.
YTD Price Performance: -12.00%
Average Trading Volume: 1,339,602
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $515.9M
See more insights into ANNX stock on TipRanks’ Stock Analysis page.
